-
Most Recent
Search Results
240 results for abv
70% of Trades Are Now Machines. Here’s How to Beat Them.
If the market feels harder to read lately… you’re not imagining it. Its character has changed. My colleague Luke Lango explains why today’s volatility is…
When Algorithms Control the Market, Patience Isn’t Enough
In this kind of market, simply buying a great company and waiting can still work. But it often requires patience and the ability to ride…
“Buy the Dip” in This Megatrend?
Drones are down – is this a good entry point?… how Jonathan Rose sizes up the opportunity set… the economics behind humanoids aren’t good for…
Volatility Is the New Normal. Breakouts Are the Edge.
In today’s Friday Digest takeover, our hypergrowth expert Luke Lango explains why modern markets behave differently than they did even a decade ago. With algorithms…
2 Breakout Stocks to Buy Immediately
Today, I’d like to share two stocks that demonstrate the power of Luke’s Breakout System – companies with hidden catalysts that could be entering the…
The AI Acceleration Curve Just Went Vertical
New benchmarks suggest AI acceleration is speeding up rapidly – and the economic consequences could be enormous.
The Stock Everyone’s Buying That AI Will Destroy
I want to bring to your attention a streaming giant that accounted for over 95 billion hours of viewing time in the first half of…
ABM’s Dividend Increase Won’t Keep it Above $30
This morning I am recommending a bearish trade on ABM Industries, Inc. (NYSE:ABM), a provider of facility services like parking, janitorial services and building and…
U.S. Strike on Iran: What Operation Epic Fury Means for Markets
Operation Epic Fury reshapes Iran’s regime. We break down oil risks, market reaction, and the AI defense surge.
Trade of the Day: AbbVie (ABBV)
In 2017, Humira raked in $18.9 billion in sales for AbbVie (ABBV) and, according to the company’s latest earnings announcement, that sales rate grew by…
Strong Buy for AbbVie (ABBV) This Week
AbbVie (ABBV) remains a Strong Buy this week based on the most current relative pricing of its shares and analysis.
Strong Buy for AbbVie (ABBV) This Week
The Strong Buy for AbbVie (ABBV) this week is based on the latest stock market rankings, and relative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
AbbVie Inc (ABBV) Is About to Steamroll the Competition
Good news for AbbVie (ABBV) shareholders: The pharmaceutical company just entered the Hepatitis C. market, while reinforcing its position in the psoriasis area. Given ABBV’s…
Trade of the Day: AbbVie Inc. (NYSE:ABBV)
AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.
7 – 10 of 240 results
